Skip to main content
. 2012 Nov;5(6):718–725. doi: 10.1242/dmm.010033

Fig. 2.

Fig. 2.

The preclinical trial phases of translational stroke research. As therapeutic agents or concepts advance in development, the experimental setting increases in complexity. It ranges from small cohorts to investigate novel (pathophysiological) mechanisms to large mixed populations with (multiple) comorbidities and additional modeling of stroke care. The final stage of preclinical development is to conduct a randomized controlled preclinical trial (RCPT), ideally in a stroke unit setting. Randomized clinical trials commence after this process has been completed, and are based on evidence gained in preclinical testing.